Bausch Health Americas, Inc. clinical trials

Acquired by Bausch Health Companies Inc., Sep 28, 2010 · source ↗

The registry lists 213 studies whose lead sponsor is Bausch Health Americas, Inc.. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 20, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 213. List all 213 → · All Bausch Health Companies Inc. studies →

• Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)RecruitingNCT07428538Phase 3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FCRecruitingNCT07723924Phase 2

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative ColitisNot yet recruitingNCT05976802Phase 4

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive DisorderNot yet recruitingNCT02129751Phase 4

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency TreatmentRecruitingNCT07187297Not applicable

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute DiarrheaRecruitingNCT07285785Phase 4

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Study to Assess Safety, Pharmacokinetics, and Treatment Effect of CabtreoRecruitingNCT07524946Phase 4

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe PsoriasisEnrolling by invitationNCT03254667

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative ColitisRecruitingNCT04314375Phase 4

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Safety and Efficacy of IDP-118 in Participants With Plaque PsoriasisCompletedNCT02462122Phase 3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• The Plecanatide Irritable Bowel Syndrome With Constipation Safety and Efficacy Study (IBS-C)CompletedNCT02387359Phase 3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Participants With Acne VulgarisCompletedNCT03664752Phase 3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne VulgarisCompletedNCT02932306Phase 3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Safety and Efficacy of IDP-122 in Participants With Plaque PsoriasisCompletedNCT02515097Phase 3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque PsoriasisActive, not recruitingNCT03987763Phase 4

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work ProductivityActive, not recruitingNCT05132231

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne VulgarisCompletedNCT07205107

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin ResurfacingActive, not recruitingNCT07214272Not applicable

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque PsoriasisCompletedNCT03988439Phase 4

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)CompletedNCT03596905Phase 2

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle GelCompletedNCT04892706Phase 2

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19_#2WithdrawnNCT04356677Phase 1

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric SubjectsActive, not recruitingNCT03240809Phase 4

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• 10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used PimecrolimusActive, not recruitingNCT00568997

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted before Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With CirrhosisActive, not recruitingNCT05297448Phase 3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative ColitisCompletedNCT04857112Phase 2

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in CirrhosisActive, not recruitingNCT05071716Phase 3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell DiseaseCompletedNCT05098028Phase 2

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne VulgarisCompletedNCT04214639Phase 3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne VulgarisCompletedNCT04214652Phase 3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic EncephalopathyTerminatedNCT01846663Phase 4

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired SubjectsTerminatedNCT03818672Phase 4

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength TreatmentCompletedNCT05027282Not applicable

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)CompletedNCT03002571Phase 3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult SubjectsCompletedNCT03058783Phase 3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)CompletedNCT03515044Phase 2

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Naloxone and Intravenous Methylnaltrexone Effects on Bladder FunctionCompletedNCT01367561Phase 1

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne VulgarisCompletedNCT03664739Phase 3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent RegimenCompletedNCT04149587

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy VolunteersCompletedNCT05229510Phase 1

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne VulgarisCompletedNCT03170388Phase 2

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe OnychomycosisCompletedNCT02812771Phase 4

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19CompletedNCT04551768Phase 1

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• (C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid ArthritisCompletedNCT02047604Phase 2

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Randomised, Placebo-controlled Safety and Pharmacokinetics Study of Novel Rifaximin Formulations in Healthy VolunteersCompletedNCT04529811Phase 1

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)CompletedNCT01983306Phase 2

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic CancerWithdrawnNCT04151719Phase 3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic CancerWithdrawnNCT04083651Phase 2/3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)CompletedNCT03168334Phase 3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.

• A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)CompletedNCT03168321Phase 3

  Sponsor listed in the registry: Bausch Health Americas, Inc. · First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc.